Relmacabtagene Autoleucel

Preferred Label : Relmacabtagene Autoleucel;

NCIt synonyms : Autologous Anti-CD19 CAR T-cells JWCAR029; Autologous CD19-targeted CAR T Cells JWCAR029; Relma-cel;

NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.;

UNII : K5CXA4X5U8;

Molecule name : JWCAR-029; JWCAR 029;

NCI Metathesaurus CUI : CL562704;

Details

Origin ID

C155878;

UMLS CUI

C5551406;

Currated CISMeF NLP mapping
- relmacabtagene autoleucel [MeSH Supplementary Concept]
- relmacabtagene autoleucel [MeSH concept]
Semantic type(s)
- Cell [UMLS semantic type]
UMLS correspondences (same concept)
- relmacabtagene autoleucel [MeSH Supplementary Concept]
chemical_or_drug_affects_cell_type_or_tissue
- Cytotoxic T-Lymphocyte [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Sensitization [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Immunopotentiation [NCIt concept]
- T-Cell Activation [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients